Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: ROY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the U.S. Food and Drug Administration (USFDA).
The Bloxiverz brand and generic had U.S. sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health*.
Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 ml and 10 mg/10 ml multi-dose vials.
Bloxiverz is a registered trademark of Avadel Legacy Pharmaceuticals LLC.
*IMS National Sales Perspective: Retail and Non-Retail MAT July 2018
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2529.3 as compared to the previous close of Rs. 2525.05. The total number of shares traded during the day was 282830 in over 3104 trades.
The stock hit an intraday high of Rs. 2572.9 and intraday low of 2490.55. The net turnover during the day was Rs. 711630934.